1. Home
  2. ASAN vs LIVN Comparison

ASAN vs LIVN Comparison

Compare ASAN & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Asana Inc.

ASAN

Asana Inc.

HOLD

Current Price

$6.97

Market Cap

3.4B

Sector

Technology

ML Signal

HOLD

Logo LivaNova PLC

LIVN

LivaNova PLC

HOLD

Current Price

$61.14

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASAN
LIVN
Founded
2008
1987
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.5B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
ASAN
LIVN
Price
$6.97
$61.14
Analyst Decision
Hold
Buy
Analyst Count
14
7
Target Price
$12.46
$72.43
AVG Volume (30 Days)
6.6M
642.6K
Earning Date
06-02-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
27.93
N/A
EPS
N/A
N/A
Revenue
$790,806,000.00
N/A
Revenue This Year
$10.19
$9.79
Revenue Next Year
$7.91
$6.63
P/E Ratio
N/A
N/A
Revenue Growth
9.25
N/A
52 Week Low
$5.38
$35.00
52 Week High
$19.00
$71.58

Technical Indicators

Market Signals
Indicator
ASAN
LIVN
Relative Strength Index (RSI) 60.71 42.45
Support Level $6.51 $58.14
Resistance Level $8.20 $65.61
Average True Range (ATR) 0.41 1.98
MACD 0.14 -0.55
Stochastic Oscillator 93.64 30.17

Price Performance

Historical Comparison
ASAN
LIVN

About ASAN Asana Inc.

Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.

About LIVN LivaNova PLC

UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Share on Social Networks: